Barcelona, May 2017 - Sagetis Biotech is pleased to announce that Sagetis’ Chief Executive Officer, Eduard Diviu and R&D Manager, Dr. Anna Cascante, will be attending Annual Bio€quity Europe in Paris (France) from the 22th - 23th April 2017. Additionally, Eduard will hold a presentation on Tuesday, May 23 at 11:50 am (Paris local time). If you wish to meet with us, please get in touch and we will arrange a meeting.
Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected Presenting Companies.
Now celebrating its 18th meeting, Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from 24 nations attended Bio€quity Europe last year in Copenhagen.
About Sagetis Biotech
Sagetis Biotech is devoted to developing an innovative gene delivery technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors. Privately funded and based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.